Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697389 | 0.93 | MAPK14 (0.40) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 | |
| SCHEMBL2649615 | 0.93 | MAPK14 (0.36) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 | |
| SCHEMBL1341749 | 0.91 | SMN1; SMN2 (0.38) | MAPK14MAPK13SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1340443 | 0.91 | MAPK14 (0.40) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 | |
| SCHEMBL1343592 | 0.89 | MAPK14 (0.40) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 | |
| SCHEMBL6696998 | 0.87 | MAPK14 (0.40) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 | |
| SCHEMBL2649620 | 0.86 | MAPK14 (0.33) | MAPK14MAPK13AURKAAURKB | |
| SCHEMBL1342766 | 0.86 | SMN1; SMN2 (0.39) | MAPK14MAPK13SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1341694 | 0.86 | SMN1; SMN2 (0.40) | MAPK14MAPK13SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1342322 | 0.85 | MAPK14 (0.40) | MAPK14MAPK13AURKAAURKBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPK14 1028/4885MAPK13 687/4885AURKA 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.